Eros Ferrazzí

2.5k total citations · 1 hit paper
48 papers, 1.8k citations indexed

About

Eros Ferrazzí is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Eros Ferrazzí has authored 48 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 16 papers in Molecular Biology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Eros Ferrazzí's work include Cancer Treatment and Pharmacology (8 papers), Colorectal Cancer Treatments and Studies (6 papers) and Cancer therapeutics and mechanisms (5 papers). Eros Ferrazzí is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Colorectal Cancer Treatments and Studies (6 papers) and Cancer therapeutics and mechanisms (5 papers). Eros Ferrazzí collaborates with scholars based in Italy, Belgium and United States. Eros Ferrazzí's co-authors include Milena Gusella, Angelo Veronese, Massimo Negrini, Silvia Sabbioni, Luigi Bolondi, Laura Gramantieri, George A. Calin, Manuela Ferracin, Carlo M. Croce and Chang‐Gong Liu and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Eros Ferrazzí

46 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cyclin G1 Is a Target of miR-122a, a MicroRNA Frequently Down-regulated in Human Hepatocellular Carcinoma

2007 670 citations Laura Gramantieri, Manuela Ferracin et al. Cancer Research profile →

Peers

Countries citing papers authored by Eros Ferrazzí

Since Specialization

Citations

This map shows the geographic impact of Eros Ferrazzí's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eros Ferrazzí with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eros Ferrazzí more than expected).

Fields of papers citing papers by Eros Ferrazzí

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eros Ferrazzí. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eros Ferrazzí. The network helps show where Eros Ferrazzí may publish in the future.

Co-authorship network of co-authors of Eros Ferrazzí

This figure shows the co-authorship network connecting the top 25 collaborators of Eros Ferrazzí. A scholar is included among the top collaborators of Eros Ferrazzí based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eros Ferrazzí. Eros Ferrazzí is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	ISUOG Consensus Statement on maternal hemodynamic assessment in hypertensive disorders of pregnancy and fetal growth restriction	Ultrasound in Obstetrics and Gynecology	Tamara Stampalija, C. Lees et al.	1
2	Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer	British Journal of Cancer	Milena Gusella, A.C. Frigo et al.	77
3	Predictive value of hematological and phenotypical parameters on postchemotherapy leukocyte recovery	Cytometry Part B Clinical Cytometry	Antonio Bononi, Francesco Lanza et al.	8
4	Cyclin G1 Is a Target of miR-122a, a MicroRNA Frequently Down-regulated in Human Hepatocellular Carcinoma breakdown →	Cancer Research	Laura Gramantieri, Manuela Ferracin et al.	670
5	Pharmacokinetic and demographic markers of 5-fluorouracil toxicity in 181 patients on adjuvant therapy for colorectal cancer	Annals of Oncology	Milena Gusella, G Crepaldi et al.	43
6	A novel G/C single-nucleotide polymorphism in the double 28-bp repeat thymidylate synthase allele	The Pharmacogenomics Journal	Milena Gusella, G Crepaldi et al.	21
7	Effect of Hemodialysis on the Metabolic Clearance of 5-Fluorouracil in a Patient With End-Stage Renal Failure	Therapeutic Drug Monitoring	Milena Gusella, G. Cartei et al.	18
8	Frequent Aberrant Methylation of the *CDH4* Gene Promoter in Human Colorectal and Gastric Cancer	Cancer Research	Elena Miotto, Silvia Sabbioni et al.	81
9	CXCR-4 Expression on Bone Marrow CD34 ⁺ Cells Prior to Mobilization Can Predict Mobilization Adequacy in Patients with Hematologic Malignancies	Journal of Hematotherapy & Stem Cell Research	Melissa Dabusti, Francesco Lanza et al.	14
10	Multigene Methylation Analysis of Gastrointestinal Tumors	Molecular Diagnosis	Silvia Sabbioni, Elena Miotto et al.	34
11	Bioimpedance vector pattern in cancer patients without disease versus locally advanced or disseminated disease	Nutrition	Silvia Toso, Antonio Piccoli et al.	58
12	Phase II trial of interferon‐α‐2a plus psolaren with ultraviolet light A in patients with cutaneous T‐cell lymphoma	Cancer	Vanna Chiarion‐Sileni, Antonio Bononi et al.	60
13	Relationships between body composition parameters and fluorouracil pharmacokinetics	British Journal of Clinical Pharmacology	Milena Gusella, Eros Ferrazzí et al.	75
14	New Limited Sampling Strategy for Determining 5-Fluorouracil Area Under the Concentration-Time Curve After Rapid Intravenous Bolus	Therapeutic Drug Monitoring	Milena Gusella, Eros Ferrazzí et al.	14
15	Elderly Ovarian Cancer: Treatment with Mitoxantrone–Carboplatin	Gynecologic Oncology	Maria Ornella Nicoletto, Grazia Artioli et al.	7
16	Altered tissue electric properties in lung cancer patients as detected by bioelectric impedance vector analysis	Nutrition	Silvia Toso, Antonio Piccoli et al.	172
17	Pharmacokinetics of intraperitoneal hyperthermic perfusion with mitoxantrone in ovarian cancer	Cancer Chemotherapy and Pharmacology	Maria Ornella Nicoletto, F. Galeotti et al.	28
18	Phase I–II intraperitoneal mitoxantrone in advanced pretreated ovarian cancer	European Journal of Cancer	Maria Ornella Nicoletto, Roberto Padrini et al.	10
19	Antiviral activity of gyrase inhibitors norfloxacin,coumermycin A1 and nalidixic acid	Biochemical Pharmacology	Eros Ferrazzí, Marta Peracchi et al.	29
20	Tossicità della Bleomicina Somministrata in Infusione Continua ad Alte Dosi	Tumori Journal	A. Fornasiero, Otello Daniele et al.	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact